Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Change In Working Capital : $-33.75 Mil (TTM As of Mar. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals Change In Working Capital?

Spectrum Pharmaceuticals's change in working capital for the quarter that ended in Mar. 2023 was $-18.18 Mil.

Spectrum Pharmaceuticals's change in working capital for the fiscal year that ended in Dec. 2022 was $-35.22 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Spectrum Pharmaceuticals Change In Working Capital Historical Data

The historical data trend for Spectrum Pharmaceuticals's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals Change In Working Capital Chart

Spectrum Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Working Capital

Get a 7-Day Free Trial

22.63

-21.89

-12.53

2.65

-35.22

Spectrum Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Change In Working Capital	Get a 7-Day Free Trial															-19.65	0.16	1.33	-17.06	-18.18

Spectrum Pharmaceuticals Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-33.75 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Spectrum Pharmaceuticals Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110

Website

https://www.sppirx.com

Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.

Executives

Juhyun Lim	director	11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick	director	C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan	officer: See Remarks	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan	officer: Chief Legal Officer	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga	director, officer: CEO & President	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel	officer: Chief Medical Officer	4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas	director	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson	officer: EVP & Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon	officer: Chief Commercial Officer	11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak	director	201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii	director	157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner	director	157 TEHCNOLOGY DRIVE, IRVINE CA 92618